Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

By Christopher M. Clark, M. Pontecorvo, T. Beach, Barry J. Bedell, R. Coleman, P. Doraiswamy, Adam Fleisher, Eric M. Reiman, M. Sabbagh, C. Sadowsky and 9 more. Lancet Neurology, 2012

748 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021 (2021, positive): “…increased cortical retention of the tracer in regions of Aβ deposition within the brain (74), thus confirming the presence of Aβ plaques in the brain (74, 75) and directly quantify brain amyloid pathology (76), thus making it a useful tool to supplement a clinical battery to diagnose AD (3, 74).”
Tau PET imaging in aging and early Alzheimer’s disease (2015, background): “The detection of Ab by PET tracers with very high molecular specificity has been confirmed by histopathologic correlation studies.(4,5) More recently, Kolb and”
Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. (2017, methodology): “M A PET was a 10-minute (two 5-minutes frames) 3-Dimensional acquisition, 50 minutes after the injection of an intravenous bolus of 370 MBq (10 mCi) of 18 F-Florbetapir (Clark et al., 2012).”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “PET studies that use tracers that specifically bind amyloid (C11PiB [Klunk et al. 2004; Ikonomovic et al. 2008], F18-florbetapir [Wong et al. 2010; Clark et al. 2011, 2012], F18-flutemetamol [Vandenberghe et al. 2010; Wolk et al. 2011], and F18-florbetaben [Rowe et al. 2008]) can noninvasively…”